Patents by Inventor Christopher James Sloey

Christopher James Sloey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REDUCING VISCOSITY OF PHARMACEUTICAL FORMULATIONS
    Publication number: 20240066124
    Abstract: A method for reducing the viscosity of a pharmaceutical formulation is provided that utilizes a viscosity-reducing concentration of an excipient selected from the group consisting of the n-acetyl arginine, n-acetyl lysine, n-acetyl proline and mixtures thereof in combination with a therapeutiv protein. A stable pharmaceutical formulation is also provided.
    Type: Application
    Filed: October 24, 2023
    Publication date: February 29, 2024
    Applicant: AMGEN INC.
    Inventors: Christopher James SLOEY, Sekhar KANAPURAM
  • Methods for reducing the viscosity of liquid pharmaceutical formulations comprising therapeutic proteins
    Patent number: 11813328
    Abstract: A method for reducing the viscosity of a pharmaceutical formulation is provided that utilizes a viscosity-reducing concentration of an excipient selected from the group consisting of the n-acetyl arginine, n-acetyl lysine, n-acetyl proline and mixtures thereof in combination with a therapeutiv protein. A stable pharmaceutical formulation is also provided.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: November 14, 2023
    Assignee: AMGEN INC.
    Inventors: Christopher James Sloey, Sekhar Kanapuram
  • LOW-VISCOSITY, HIGH CONCENTRATION EVOLOCUMAB FORMULATIONS AND METHODS OF MAKING THE SAME
    Publication number: 20230226177
    Abstract: Provided herein are formulations of PCSK9-binding polypeptides, such as those comprising evolocumab, that comprise N-acetyl arginine and have reduced viscosities when compared to formulations lacking N-acetyl arginine. Provided herein are also methods of formulating such compositions that are advantageous in that they conserve certain components. Such formulations comprising PCSK9-binding polypeptides can be administered to patients to treat and/or prevent PCSK9-related diseases, conditions, and disorders.
    Type: Application
    Filed: August 23, 2022
    Publication date: July 20, 2023
    Inventors: Christopher James SLOEY, Sekhar KANAPURAM, Huanchun CUI, Chio Mui CHAN, Elaheh BINABAJI
  • Aqueous Formulation of Erythropoiesis Stimulating Protein Stabilised by Antioxidants for Parenteral Administration
    Publication number: 20230126688
    Abstract: The present invention relates to stable aqueous protein formulations. In particular, disclosed herein are therapeutic protein formulations suitable for parenteral administration having one or more antioxidants.
    Type: Application
    Filed: September 1, 2022
    Publication date: April 27, 2023
    Inventors: Christopher James Sloey, Jason Ko, Tiansheng Li
  • Low-viscosity, high concentration evolocumab formulations and methods of making the same
    Patent number: 11464857
    Abstract: Provided herein are formulations of PCSK9-binding polypeptides, such as those comprising evolocumab, that comprise N-acetyl arginine and have reduced viscosities when compared to formulations lacking N-acetyl arginine. Provided herein are also methods of formulating such compositions that are advantageous in that they conserve certain components. Such formulations comprising PCSK9-binding polypeptides can be administered to patients to treat and/or prevent PCSK9-related diseases, conditions, and disorders.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: October 11, 2022
    Assignee: AMGEN INC.
    Inventors: Christopher James Sloey, Sekhar Kanapuram, Huanchun Cui, Chio Mui Chan, Elaheh Binabaji
  • Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
    Patent number: 11433134
    Abstract: The present invention relates to stable aqueous protein formulations. In particular, disclosed herein are therapeutic protein formulations suitable for parenteral administration having one or more antioxidants.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: September 6, 2022
    Assignee: AMGEN INC.
    Inventors: Christopher James Sloey, Jason Ko, Tiansheng Li
  • THE USE OF LOW MOLECULAR WEIGHT POLYVINYLPYRROLIDONE (PVP) TO REDUCE VISCOSITY OF HIGH CONCENTRATION PROTEIN FORMULATIONS
    Publication number: 20220226477
    Abstract: Disclosed herein are pharmaceutical compositions (formulations) having reduced viscosity, using a low molecular weight polyvinylpyrrolidone (povidone) in the case of high therapeutic protein concentration (?70 mg/ml) formulations. The addition of arginine, such as arginine monohydrochloride or N-acetyl arginine, can further reduce viscosity. Appropriate therapeutic proteins include antibodies, such as monoclonal antibodies, and derivatives, fragments, and analogues thereof.
    Type: Application
    Filed: April 22, 2020
    Publication date: July 21, 2022
    Inventor: Christopher James SLOEY
  • PHARMACEUTICAL FORMULATIONS
    Publication number: 20210069334
    Abstract: A method of stabilizing an aqueous protein or antibody formulation is disclosed herein. Additionally, stable pharmaceutical formulations are contemplated which comprise a biologically active protein, a destabilizing concentration of preservative and a stabilizing concentration of osmolyte.
    Type: Application
    Filed: April 22, 2020
    Publication date: March 11, 2021
    Inventors: Tiansheng LI, Christopher James SLOEY
  • Pharmaceutical Formulations
    Publication number: 20200276313
    Abstract: A stable pharmaceutical formulation is provided that comprises a biologically active protein and an excipient selected from caritine, creatine or creatinine.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: Christopher James Sloey, Camille Vergara, Jason Ko, Tiansheng Li
  • Pharmaceutical formulations
    Patent number: 10668154
    Abstract: A method of stabilizing an aqueous protein or antibody formulation is disclosed herein. Additionally, stable pharmaceutical formulations are contemplated which comprise a biologically active protein, a destabilizing concentration of preservative and a stabilizing concentration of osmolyte.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: June 2, 2020
    Assignee: Amgen Inc.
    Inventors: Tiansheng Li, Christopher James Sloey
  • Pharmaceutical formulations
    Patent number: 10653781
    Abstract: A stable pharmaceutical formulation is provided that comprises a biologically active protein and an excipient selected from carnitine, creatine or creatinine.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: May 19, 2020
    Assignee: AMGEN INC.
    Inventors: Christopher James Sloey, Camille Gleason, Jason Ko, Tiansheng Li
  • N-ACETYLATED AND NON-ACETYLATED DIPEPTIDES CONTAINING ARGININE TO REDUCE THE VISCOSITY OF VISCOUS COMPOSITIONS OF THERAPEUTIC POLYPEPTIDES
    Publication number: 20200048367
    Abstract: Provided herein are excipients capable of effectively reducing the viscosity of polypeptide (e.g., therapeutic polypeptide) formulations. The viscosity reducing excipients are dipeptides containing arginine at the carboxy terminus and N-acetylated serine or N-acetylated proline at the N-terminus. Glutamate-arginine is also disclosed as a viscosity-reducing dipeptide. Among the disclosed methods, methods of reducing the viscosities of such formulations are also provided.
    Type: Application
    Filed: April 27, 2018
    Publication date: February 13, 2020
    Applicant: Amgen Inc.
    Inventors: Neeraj Jagdish AGRAWAL, Pavan GHATTYVENKATAKRISHNA, Sekhar KANAPURAM, Christopher James SLOEY
  • LOW-VISCOSITY, HIGH CONCENTRATION EVOLOCUMAB FORMULATIONS AND METHODS OF MAKING THE SAME
    Publication number: 20180237501
    Abstract: Provided herein are formulations of PCSK9-binding polypeptides, such as those comprising evolocumab, that comprise N-acetyl arginine and have reduced viscosities when compared to formulations lacking N-acetyl arginine. Provided herein are also methods of formulating such compositions that are advantageous in that they conserve certain components. Such formulations comprising PCSK9-binding polypeptides can be administered to patients to treat and/or prevent PCSK9-related diseases, conditions, and disorders.
    Type: Application
    Filed: February 22, 2018
    Publication date: August 23, 2018
    Applicant: AMGEN INC.
    Inventors: Christopher James SLOEY, Sekhar KANAPURAM, Huanchun CUI, Chio Mui CHAN, Elaheh BINABAJI
  • REDUCING VISCOSITY OF PHARMACEUTICAL FORMULATIONS
    Publication number: 20170333559
    Abstract: A method for reducing the viscosity of a pharmaceutical formulation is provided that utilizes a viscosity-reducing concentration of an excipient selected from the group consisting of the n-acetyl arginine, n-acetyl lysine, n-acetyl proline and mixtures thereof in combination with a therapeutiv protein. A stable pharmaceutical formulation is also provided.
    Type: Application
    Filed: October 22, 2015
    Publication date: November 23, 2017
    Applicant: AMGEN INC.
    Inventors: Christopher James SLOEY, Sekhar KANAPURAM
  • PHARMACEUTICAL FORMULATIONS
    Publication number: 20170049895
    Abstract: A stable pharmaceutical formulation is provided that comprises a biologically active protein and an excipient selected from carnitine, creatine or creatinine.
    Type: Application
    Filed: April 1, 2016
    Publication date: February 23, 2017
    Inventors: Christopher James Sloey, Camille Gleason, Jason Ko, Tiansheng Li
  • Pharmaceutical formulations
    Patent number: 9320797
    Abstract: A stable pharmaceutical formulation is provided that comprises a biologically active protein and an excipient selected from carnitine, creatine or creatinine.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: April 26, 2016
    Assignee: AMGEN INC.
    Inventors: Christopher James Sloey, Camille Vergara, Jason Ko, Tiansheng Li
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20150335748
    Abstract: A method of stabilizing an aqueous protein or antibody formulation is disclosed herein. Additionally, stable pharmaceutical formulations are contemplated which comprise a biologically active protein, a destabilizing concentration of preservative and a stabilizing concentration of osmolyte.
    Type: Application
    Filed: February 4, 2015
    Publication date: November 26, 2015
    Applicant: Amgen Inc.
    Inventors: Tiangsheng LI, Christopher James Sloey
  • Pharmaceutical formulations
    Patent number: 8980256
    Abstract: A method of stabilizing an aqueous protein or antibody formulation is disclosed herein. Additionally, stable pharmaceutical formulations are contemplated which comprise a biologically active protein, a destabilizing concentration of preservative and a stabilizing concentration of osmolyte.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: March 17, 2015
    Assignee: Amgen Inc.
    Inventors: Tiansheng Li, Christopher James Sloey
  • AQUEOUS FORMULATION OF ERYTHROPOIESIS STIMULATING PROTEIN STABILISED BY ANTIOXIDANTS FOR PARENTERAL ADMINISTRATION
    Publication number: 20140294859
    Abstract: The present invention relates to stable aqueous protein formulations. In particular, disclosed herein are therapeutic protein formulations suitable for parenteral administration having one or more antioxidants.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Applicant: AMGEN INC.
    Inventors: Christopher James Sloey, Jason Ko, Tiansheng Li
  • Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
    Patent number: 8796206
    Abstract: The present invention relates to stable aqueous protein formulations. In particular, disclosed herein are therapeutic protein formulations suitable for parenteral administration having one or more antioxidants.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: August 5, 2014
    Assignee: Amgen Inc.
    Inventors: Christopher James Sloey, Jason Ko, Tiansheng Li